bucindolol Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity. It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted.   Wikipedia

Chemistry

  • SMILES: CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc3ccccc3C#N
  • InChIKey: FBMYKMYQHCBIGU-UHFFFAOYSA-N
  • Mol. Mass: 363.46
  • ALogP: 3.39
  • ChEMBL Molecules:
    bucindolol  
    bucindolol hydrochloride  
More Chemistry

Pharmacology

Alternative names

benzonitrile, 2-(2-hydroxy-3-((2-(1h-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)-, monohydrochloride | bucindolol | bucindolol hcl | bucindolol hydrochloride | mj 13105 | mj-13105-1

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Atrial Fibrillation (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue